Publications by authors named "Ivan Ischenko"

Claim this Profile
A
Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer.
Yue Zhao, Lu Zhao, Ivan Ischenko, Qi Bao, Bettina Schwarz

Target Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
Hanno Niess, Peter Camaj, Andrea Renner, Ivan Ischenko, Yue Zhao

Target Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer stem cells and angiogenesis.
Yue Zhao, Qi Bao, Andrea Renner, Peter Camaj, Martin Eichhorn, Ivan Ischenko

Int J Dev Biol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis.
Andrea S Rothmeier, Uta M Schneiders, Romina M Wiedmann, Ivan Ischenko, Christiane J Bruns

Int J Cancer· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for surgical complications in distal pancreatectomy.
Hendrik Seeliger, Simone Christians, Martin K Angele, Axel Kleespies, Martin E Eichhorn, Ivan Ischenko

Am J Surg· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer.
Martin E Eichhorn, Ivan Ischenko, Siiri Luedemann, Sebastian Strieth, Armine Papyan

Int J Cancer· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications.
Ivan Ischenko, Hendrik Seeliger, Axel Kleespies, Martin K Angele, Martin E Eichhorn

Langenbecks Arch Surg· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells.
Peter Camaj, Hendrik Seeliger, Ivan Ischenko, Stefan Krebs, Helmut Blum

Biol Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma.
Christoph Zischek, Hanno Niess, Ivan Ischenko, Claudius Conrad, Ralf Huss

Ann Surg· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic activity and chemotherapy resistance in human pancreatic cancer--influence of cancer stem cells.
Ivan Ischenko, Hendrik Seeliger, Karl-Walter Jauch, Christiane J Bruns

Surgery· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the marine compound spongistatin 1 links the inhibition of PKCalpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis.
Andrea S Rothmeier, Ivan Ischenko, Jos Joore, Dorota Garczarczyk, Robert Fürst

FASEB J· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer stem cells: how can we target them?
Ivan Ischenko, Hendrik Seeliger, Moshe Schaffer, Karl-Walter Jauch, Christiane J Bruns

Curr Med Chem· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma.
Hendrik Seeliger, Peter Camaj, Ivan Ischenko, Axel Kleespies, Enrico N De Toni

Mol Cancer Res· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine.
Axel Kleespies, Ivan Ischenko, Martin E Eichhorn, Hendrik Seeliger, Christiane Amendt

Clin Cancer Res· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Ivan Ischenko, Markus Guba, Maksim Yezhelyev, Armine Papyan, Gerald Schmid

Angiogenesis· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Claudius Conrad, Ivan Ischenko, Gudrun Köhl, Ulrich Wiegand, Markus Guba

Anticancer Drugs· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
Gerald Schmid, Markus Guba, Ivan Ischenko, Armine Papyan, Mareile Joka

J Cell Biochem· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF.
Markus Guba, Maksim Yezhelyev, Martin E Eichhorn, Gerald Schmid, Ivan Ischenko

Blood· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
Daniela Bruell, Christiane J Bruns, Maksim Yezhelyev, Michael Huhn, Jürgen Müller, Ivan Ischenko

Int J Mol Med· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis